Neuropsychological tests were grouped into nine domains (Table S4), patients were categorized according to their APOE ε4 carrier status, and their cognitive impairment outcome was classified into severe or non-severe impairments (Tables S5 and S6). This evidence concerns the gene APOE and Cognitive impairment.